Date: 2012-05-02
Type of information: Development agreement
Compound: EVT401
Company: Evotec (Germany) Conba Pharmaceutical (China)
Therapeutic area: Inflammatory diseases
Type agreement: development
licensing
Action mechanism: EVT401 is a P2X7 antagonist. The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines such as IL-1ß.
Disease: inflammatory diseases
Details: Evotec and Conba Pharmaceutical have announced the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease (COPD) and endometriosis in China. Evotec has completed the first Phase I, single dose study of EVT 401 in 2010. Conba Pharmaceutical will initiate further clinical trials with EVT 401 in China in inflammatory diseases.
The agreement grants Conba Pharmaceutical exclusive rights to develop and commercialise the compound for the Chinese market. Evotec will have the right to reference clinical data produced by Conba Pharmaceutical to support potential further development of EVT 401 in other territories. In August 2011 EVT401 was partnered in animal health indication with a major animal health company.
Financial terms: Evotec receives a small upfront payment, development and commercial milestone payments in excess of € 60 million, and tiered double-digit royalties on net sales.
Latest news:
